Delivery Order SPE2DB24D2101-SPE2DB25FKMGP
Award Date 7/14/25
Potential Completion Date 8/4/25
Potential Value $8.1K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for Ibrance 75 mg capsules (21-count unit) on July 22, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used in cancer treatment, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) with a ceiling value of $8,118.08. This firm fixed-price delivery order, which is expected to be completed by June 24, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription cancer treatment medication,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) valued at $8,123.96 with an ultimate completion date of September 26, 2025. This contract represents a firm fixed-price delivery order under a non-set-aside competitive procurement, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Ibrance is a prescription pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,118.08, with completion scheduled for August 22, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA's medical supply chain. The product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 125 mg capsules (21-count packaging). This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The order is scheduled for completion by October 9, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This...
- The Defense Logistics Agency awarded a $8,122.48 delivery order to AmerisourceBergen Drug Corp for 7 tablets of Ibrance 100 mg on June 5, 2025, with completion scheduled for June 27, 2025. This competitively awarded, firm fixed-price order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ibrance is a brand-name oncology medication used in cancer treatment, reflecting the pharmaceutical distribution services that...
- The Defense Logistics Agency awarded a delivery order valued at $25,679.52 to AmerisourceBergen Drug Corp for 7 tablets of Ibrance 100 mg on October 20, 2025, with an ultimate completion date of November 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription medication used in oncology treatment, and this delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) on June 2, 2025, with an ultimate completion date of June 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's Conshohocken, Pennsylvania location. Ibrance is a prescription oncology medication used in breast cancer treatment, reflecting the Defense...